Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection

Gene Therapy

Volumn 19, Issue 3, 2012, Pages 246-254

  Van Der Loo, J C M ^a   Swaney, W P ^b   Grassman, E ^a   Terwilliger, A ^a   Higashimoto, T ^a   Schambach, A ^c   Baum, C ^c   Thrasher, A J ^d,e   Williams, D A ^f   Nordling, D L ^a   Reeves, L ^g   Malik, P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b USA   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Great Ormond Street Hospital NHS Trust ^*  (United Kingdom)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

retrovirus; bioreactor; cGMP; process development; scale up; self inactivating

Indexed keywords

CALCIUM PHOSPHATE; CYCLIC GMP; GAMMA RETROVIRUS VECTOR; PLASMID VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOREACTOR; CELL DENSITY; CELL EXPANSION; CELL GROWTH; CELL STRAIN; CELL STRAIN 293T; CELL VIABILITY; CONTROLLED STUDY; ECOTROPIC VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SUPERNATANT; TRANSIENT TRANSFECTION; VIRAL GENE THERAPY;

ANIMALS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; BIOTECHNOLOGY; CELL LINE; GAMMARETROVIRUS; GENETIC VECTORS; HUMANS; MICE; QUALITY CONTROL; TRANSFECTION;

BOVINAE;

EID: 84858008742     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.102     Document Type: Article

References (51)

1. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419. (Pubitemid 37296260)
2. Williams DA, Baum C. Medicine. Gene therapy - new challenges ahead. Science 2003; 302: 400-401. (Pubitemid 37296253)
3. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-3150.
4. Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, Loew R et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Therapy 2006; 13: 1524-1533. (Pubitemid 44567149)
5. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198. (Pubitemid 16043003)
6. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471. (Pubitemid 28471781)
7. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880. (Pubitemid 28520853)
8. Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008; 16: 590-598. (Pubitemid 351315000)
9. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-725. (Pubitemid 351426173)
10. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696. (Pubitemid 43882120)
11. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
12. Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H et al. A new PG13- based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Therapy 2010; 17: 272-280.
13. Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, Greene M et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009; 113: 5104-5110.
14. Jordan M, Wurm F. Transfection of adherent and suspended cells by calcium phosphate. Methods 2004; 33: 136-143. (Pubitemid 38569658)
15. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996; 2: 876-882. (Pubitemid 26296757)
16. Sastry L, Xu Y, Cooper R, Pollok K, Cornetta K. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther 2004; 15: 221-226. (Pubitemid 38210536)
17. Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011; 22: 343-356.
18. Wright JF. Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther 2009; 20: 698-706.
19. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
20. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-7301.
21. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
22. Merten OW. State-of-the-art of the production of retroviral vectors. J Gene Med 2004; 6 (Suppl 1): S105-S124.
23. Merten OW, Cruz PE, Rochette C, Geny-Fiamma C, Bouquet C, Goncalves D et al. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol Prog 2001; 17: 326-335. (Pubitemid 32663398)
24. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027. (Pubitemid 41324561)
25. Wilson JM. Gendicine: the first commercial gene therapy product. Hum Gene Ther 2005; 16: 1014-1015. (Pubitemid 41324560)
26. Pierce LN, Shabram PW. Scalability of a disposable bioreactor from 25L-500L run in perfusion mode with a CHO-based cell line: a tech review. BioProcess J 2004; 3: 51-56.
27. Segura MM, Kamen A, Trudel P, Garnier A. A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 2005; 90: 391-404. (Pubitemid 40779190)
28. Segura MM, Garnier A, Kamen A. Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. J Virol Methods 2006; 133: 82-91.
29. Segura MM, Kamen A, Garnier A. Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 2006; 24: 321-337.
30. Schambach A, Swaney WS, van der Loo JCM. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. In: Baum C (ed). Methods in Molecular Biology, vol. 506, Humana Press: Totowa, NJ, 2009, pp 191-205.
31. Hildinger M, Abel KL, Ostertag W, Baum C. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083-4089. (Pubitemid 29189853)
32. Kraunus J, Schaumann DH, Meyer J, Modlich U, Fehse B, Brandenburg G et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Therapy 2004; 11: 1568-1578. (Pubitemid 39433477)
33. Schambach A, Galla M, Maetzig T, Loew R, Baum C. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15: 1167-1173. (Pubitemid 46813620)
34. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine- DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391-400. (Pubitemid 43056905)
35. Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541-7547.
36. Grez M, Akgun E, Hilberg F, Ostertag W. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci USA 1990; 87: 9202-9206. (Pubitemid 120030593)
37. Reeves L, Smucker P, Cornetta K. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene Ther 2000; 11: 2093-2103.
38. Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R. Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 2005; 7: 1299-1310. (Pubitemid 41555436)
39. Wikstrom K, Blomberg P, Islam KB. Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy. Biotechnol Prog 2004; 20: 1198-1203. (Pubitemid 39059634)
40. Higashikawa F, Chang L. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 2001; 280: 124-131. (Pubitemid 34158058)
41. Persons DA, Baum C. Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol Ther 2011; 19: 229-231.
42. Herbst F, Ball CR, Zavidij O, Fessler S, Schmidt M, Veelken H et al. 10-Year stability of clinical-grade serum-free gamma-retroviral vector-containing medium. Gene Therapy 2011; 18: 210-212.
43. Nordling D, Kaiser A, Reeves L. Release testing of retroviral vectors and gene-modified cells. Methods Mol Biol 2009; 506: 265-279.
44. Food and Drug Administration. Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther 2001; 12: 303-314.
45. Karolewski BA, Watson DJ, Parente MK, Wolfe JH. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum Gene Ther 2003; 14: 1287-1296. (Pubitemid 37174753)
46. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388. (Pubitemid 26347130)
47. Feng Y, Liu Z, Cao H, Meng X, Qu Z, Xiong M et al. Construction of eukaryotic expression plasmid of human PRX3 and its expression in HEK-293FT cells. J Huazhong Univ Sci Technol Med Sci 2004; 24: 311-313, 321.
48. Cornetta K, Matheson L, Ballas C. Retroviral vector production in the National Gene Vector Laboratory at Indiana University. Gene Therapy 2005; 12(Suppl 1): S28-S35. (Pubitemid 41541751)
49. Przybylowski M, Hakakha A, Stefanski J, Hodges J, Sadelain M, Riviere I. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Therapy 2006; 13: 95-100. (Pubitemid 41823856)
50. Wu SC, Huang GY, Liu JH. Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol Prog 2002; 18: 617-622. (Pubitemid 34623237)
51. Schleef M, Schmidt T. Annimal-free production of ccc-supercoiled plasmids for research and clinical application. J Gene Med 2004; 6(Suppl1): S45-S53. (Pubitemid 40228016)